{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:04:32Z","timestamp":1758931472103,"version":"3.44.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"DOI":"10.7759\/cureus.93232","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T06:04:27Z","timestamp":1758866667000},"source":"Crossref","is-referenced-by-count":0,"title":["Follicular Lymphoma of the Breast With Secondary Central Nervous System Transformation and Concurrent Metastatic Melanoma: Report of a Rare Case"],"prefix":"10.7759","author":[{"given":"Pranesh","family":"Gavali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay S","family":"Kollipara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shravani","family":"Rama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26737","article-title":"Follicular lymphoma: 2023 update on diagnosis and management","volume":"97","author":"Jacobsen E","year":"2022","unstructured":"Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol. 2022, 97:1638-51. 10.1002\/ajh.26737","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link BK","year":"2013","unstructured":"Link BK, Maurer MJ, Nowakowski GS, et al.. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013, 31:3272-8. 10.1200\/JCO.2012.48.3990","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma","volume":"26","author":"Al-Tourah AJ","year":"2008","unstructured":"Al-Tourah AJ, Gill KK, Chhanabhai M, et al.. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol. 2008, 26:5165-9. 10.1200\/JCO.2008.16.0283","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.869326","article-title":"Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era","volume":"55","author":"Fletcher CD","year":"2014","unstructured":"Fletcher CD, Kahl BS. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leuk Lymphoma. 2014, 55:2228-40. 10.3109\/10428194.2013.869326","journal-title":"Leuk Lymphoma"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl327","article-title":"Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)","volume":"18","author":"Boehme V","year":"2007","unstructured":"Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007, 18:149-57. 10.1093\/annonc\/mdl327","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omad118","article-title":"Follicular lymphoma with secondary central nervous system relapse: a case report and literature review","volume":"2023","author":"Tsuboi Y","year":"2023","unstructured":"Tsuboi Y, Shimizu M, Kuroda A, Suyama T, Seki M, Shinagawa A. Follicular lymphoma with secondary central nervous system relapse: a case report and literature review. Oxf Med Case Reports. 2023, 2023:omad118. 10.1093\/omcr\/omad118","journal-title":"Oxf Med Case Reports"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: a multicentre, retrospective cohort study","volume":"3","author":"Ferreri AJM","year":"2016","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, et al.. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: a multicentre, retrospective cohort study. Lancet Haematol. 2016, 3:19-29. 10.1016\/S2352-3026(16)00036-3","journal-title":"Lancet Haematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.036","article-title":"Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07","volume":"21","author":"Batchelor T","year":"2003","unstructured":"Batchelor T, Carson K, O'Neill A, et al.. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003, 21:1044-9. 10.1200\/JCO.2003.03.036","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2017.11.10","article-title":"Diagnosis and management of breast lymphoma: a single-center report","volume":"7","author":"Orlandi A","year":"2018","unstructured":"Orlandi A, Sanchez AM, Calegari MA, et al.. Diagnosis and management of breast lymphoma: a single-center report. Transl Cancer Res. 2018, 7:S270-S280. 10.21037\/tcr.2017.11.10","journal-title":"Transl Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University","volume":"14","author":"Mac Manus MP","year":"1996","unstructured":"Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996, 14:1282-90. 10.1200\/JCO.1996.14.4.1282","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna KM","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, et al.. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003, 362:516-22. 10.1016\/s0140-6736(03)14110-4","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.573","article-title":"Lymphoplasmacytic lymphoma and marginal zone lymphoma involving bone marrow: a diagnostic dilemma. Useful clinicopathological features to accurate the diagnosis","volume":"3","author":"Garc\u00eda-Abell\u00e1s P","year":"2022","unstructured":"Garc\u00eda-Abell\u00e1s P, Ferrer G\u00f3mez A, Bueno Sacrist\u00e1n D, Piris Villaespesa M, Talavera Yag\u00fce M, Reguero Callejas ME, Garc\u00eda-Cos\u00edo M. Lymphoplasmacytic lymphoma and marginal zone lymphoma involving bone marrow: a diagnostic dilemma. Useful clinicopathological features to accurate the diagnosis. EJHaem. 2022, 3:1181-7. 10.1002\/jha2.573","journal-title":"EJHaem"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278755","article-title":"Marginal zone lymphoma: present status and future perspectives","volume":"107","author":"Cheah CY","year":"2022","unstructured":"Cheah CY, Zucca E, Rossi D, Habermann TM. Marginal zone lymphoma: present status and future perspectives. Haematologica. 2022, 107:35-43. 10.3324\/haematol.2021.278755","journal-title":"Haematologica"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.046885","article-title":"Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience","volume":"32","author":"LO CN","year":"2024","unstructured":"LO CN, HO NP, KU T, et al.. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience. Oncol Res. 2024, 32:1031-6. 10.32604\/or.2024.046885","journal-title":"Oncol Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4103\/0971-3026.125626","article-title":"FDG-PET\/CT in lymphoma","volume":"23","author":"D'souza MM","year":"2013","unstructured":"D'souza MM, Jaimini A, Bansal A, Tripathi M, Sharma R, Mondal A, Tripathi RP. FDG-PET\/CT in lymphoma. Indian J Radiol Imaging. 2013, 23:354-65. 10.4103\/0971-3026.125626","journal-title":"Indian J Radiol Imaging"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27773","article-title":"Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Olszewski AJ","year":"2013","unstructured":"Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2013, 119:629-38. 10.1002\/cncr.27773","journal-title":"Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone A","year":"2019","unstructured":"Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, L\u00f3pez-Guillermo A, Fitzgibbon J. Follicular lymphoma. Nat Rev Dis Primers. 2019, 5:83. 10.1038\/s41572-019-0132-x","journal-title":"Nat Rev Dis Primers"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard JP","year":"2019","unstructured":"Leonard JP, Trneny M, Izutsu K, et al.. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019, 37:1188-99. 10.1200\/JCO.19.00010","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.surneu.2005.08.027","article-title":"Secondary central nervous system involvement by follicular lymphoma: case report and review of the literature","volume":"65","author":"Grupka NL","year":"2006","unstructured":"Grupka NL, Seinfeld J, Ryder J, Lillehei KO, Kleinschmidt-Demasters BK. Secondary central nervous system involvement by follicular lymphoma: case report and review of the literature. Surg Neurol. 2006, 65:590-4. 10.1016\/j.surneu.2005.08.027","journal-title":"Surg Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2013.45.3.234","article-title":"A rare presentation of follicular lymphoma: cerebellar involvement, successfully treated with a combination of radiotherapy and chemotherapy","volume":"45","author":"Karadurmus N","year":"2013","unstructured":"Karadurmus N, Ataergin S, Erdem G, et al.. A rare presentation of follicular lymphoma: cerebellar involvement, successfully treated with a combination of radiotherapy and chemotherapy. Cancer Res Treat. 2013, 45:234-8. 10.4143\/crt.2013.45.3.234","journal-title":"Cancer Res Treat"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.21037\/aol-20-52","article-title":"Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review","volume":"5","author":"Krebs S","year":"2021","unstructured":"Krebs S, Barasch JG, Young RJ, Grommes C, Sch\u00f6der H. Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review. Ann Lymphoma. 2021, 5:10.21037\/aol-20-52","journal-title":"Ann Lymphoma"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.50.4339","article-title":"CD5-positive follicular lymphoma: a case report and literature review","volume":"50","author":"Sekiguchi Y","year":"2011","unstructured":"Sekiguchi Y, Imai H, Wakabayashi M, Sawada T, Ichikawa K, Komatsu N, Noguchi M. CD5-positive follicular lymphoma: a case report and literature review. Intern Med. 2011, 50:899-904. 10.2169\/internalmedicine.50.4339","journal-title":"Intern Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5045\/br.2023.2023039","article-title":"CD5+ follicular lymphoma rapidly transformed to high-grade B-cell lymphoma with double-hit: from BCL2 to MYC disruption","volume":"58","author":"Soler-Espejo E","year":"2023","unstructured":"Soler-Espejo E, Marco-Ayala J, Chen-Liang TH, L\u00f3pez-Poveda MJ, Teruel-Montoya R, Ortu\u00f1o FJ. CD5+ follicular lymphoma rapidly transformed to high-grade B-cell lymphoma with double-hit: from BCL2 to MYC disruption. Blood Res. 2023, 58:79-82. 10.5045\/br.2023.2023039","journal-title":"Blood Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/10520290500305310","article-title":"Prolymphocytoid transformation of follicular lymphoma with coexpression of CD5 and CD10","volume":"47","author":"Lau SK","year":"2006","unstructured":"Lau SK, Weiss LM, Zhang Y, Huang Q. Prolymphocytoid transformation of follicular lymphoma with coexpression of CD5 and CD10. Leuk Lymphoma. 2006, 47:541-7. 10.1080\/10520290500305310","journal-title":"Leuk Lymphoma"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.5045\/br.2018.53.1.87","article-title":"Primary CNS high-grade B-cell lymphoma, with rearrangements of MYC and BCL6 : a case report","volume":"53","author":"Sasapu A","year":"2018","unstructured":"Sasapu A, Atwal D, Insuasti-Beltran G, Jethava Y. Primary CNS high-grade B-cell lymphoma, with rearrangements of MYC and BCL6 : a case report. Blood Res. 2018, 53:87-9. 10.5045\/br.2018.53.1.87","journal-title":"Blood Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278613","article-title":"Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy","volume":"109","author":"Roschewski M","year":"2024","unstructured":"Roschewski M, Hodson DJ. Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy. Haematologica. 2024, 109:388-400. 10.3324\/haematol.2021.278613","journal-title":"Haematologica"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02227-3","article-title":"The role of surgical resection in primary central nervous system lymphoma: a single-center retrospective analysis of 70 patients","volume":"21","author":"Wu S","year":"2021","unstructured":"Wu S, Wang J, Liu W, et al.. The role of surgical resection in primary central nervous system lymphoma: a single-center retrospective analysis of 70 patients. BMC Neurol. 2021, 21:190. 10.1186\/s12883-021-02227-3","journal-title":"BMC Neurol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2217\/ijh-2017-0020","article-title":"Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS","volume":"6","author":"Nagle SJ","year":"2017","unstructured":"Nagle SJ, Shah NN, Ganetsky A, et al.. Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS. Int J Hematol Oncol. 2017, 6:113-21. 10.2217\/ijh-2017-0020","journal-title":"Int J Hematol Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1906","article-title":"High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: a retrospective study from China","volume":"8","author":"Chen C","year":"2019","unstructured":"Chen C, Sun P, Cui J, et al.. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: a retrospective study from China. Cancer Med. 2019, 8:1359-67. 10.1002\/cam4.1906","journal-title":"Cancer Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac105","article-title":"Use of rituximab, temozolomide, and radiation in recurrent and refractory primary central nervous system lymphoma in the Philippines: a retrospective analysis","volume":"4","author":"Batara JM","year":"2022","unstructured":"Batara JM, Apor AD, Mojica CV, Mondia MW. Use of rituximab, temozolomide, and radiation in recurrent and refractory primary central nervous system lymphoma in the Philippines: a retrospective analysis. Neurooncol Adv. 2022, 4:vdac105. 10.1093\/noajnl\/vdac105","journal-title":"Neurooncol Adv"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143479","article-title":"Primary central nervous system lymphoma in elderly patients: management and perspectives","author":"Morales-Martinez A","year":"2021","unstructured":"Morales-Martinez A, Lozano-Sanchez F, Duran-Pe\u00f1a A, Hoang-Xuan K, Houillier C. Primary central nervous system lymphoma in elderly patients: management and perspectives. 2021. 10.3390\/cancers13143479"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1322515","article-title":"Stereotactic body radiotherapy as a viable treatment on extracranial oligometastases in melanoma patients: a retrospective multicentric study","volume":"14","author":"Trentesaux V","year":"2024","unstructured":"Trentesaux V, Maiezza S, Bogart E, et al.. Stereotactic body radiotherapy as a viable treatment on extracranial oligometastases in melanoma patients: a retrospective multicentric study. Front Oncol. 2024, 14:1322515. 10.3389\/fonc.2024.1322515","journal-title":"Front Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaf082","article-title":"Primary central nervous system lymphoma: predictors of response to induction therapy and patterns of progression","volume":"7","author":"Cappelli L","year":"2025","unstructured":"Cappelli L, Kayne A, Newman J, et al.. Primary central nervous system lymphoma: predictors of response to induction therapy and patterns of progression. Neurooncol Adv. 2025, 7:vdaf082. 10.1093\/noajnl\/vdaf082","journal-title":"Neurooncol Adv"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051459","article-title":"A systematic review of high-dose methotrexate for adults with primary central nervous system lymphoma","volume":"15","author":"Villanueva G","year":"2023","unstructured":"Villanueva G, Guscott M, Schaiquevich P, et al.. A systematic review of high-dose methotrexate for adults with primary central nervous system lymphoma. Cancers (Basel). 2023, 15:10.3390\/cancers15051459","journal-title":"Cancers (Basel)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.6633","article-title":"Immunochemotherapy with temozolomide and rituximab for central nervous system lymphomas in an elderly population","volume":"23","author":"Spadaro P","year":"2005","unstructured":"Spadaro P, Pitini V, Arrigo C, Amata C, La Torre I, Toscano G. Immunochemotherapy with temozolomide and rituximab for central nervous system lymphomas in an elderly population. J Clin Oncol. 2005, 23:6633. 10.1200\/jco.2005.23.16_suppl.6633","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20339","article-title":"Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas","volume":"101","author":"Wong ET","year":"2004","unstructured":"Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer. 2004, 101:139-45. 10.1002\/cncr.20339","journal-title":"Cancer"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00334","article-title":"Stereotactic body radiotherapy (SBRT) for oligometastatic lung nodules: a single institution series","volume":"9","author":"Wegner RE","year":"2019","unstructured":"Wegner RE, Abel S, Hasan S, Schumacher LY, Colonias A. Stereotactic body radiotherapy (SBRT) for oligometastatic lung nodules: a single institution series. Front Oncol. 2019, 9:334. 10.3389\/fonc.2019.00334","journal-title":"Front Oncol"},{"key":"ref38","doi-asserted-by":"crossref","DOI":"10.1037\/0278-6133.24.5.508","article-title":"Optimistic personality predicts psychosocial well-being in long-term breast cancer survivors","volume":"24","author":"Carver CS","year":"2005","unstructured":"Carver CS, Smith RG, Antoni MH, Petronis VM, Weiss S, Derhagopian RP. Optimistic personality predicts psychosocial well-being in long-term breast cancer survivors. Health Psychol. 2005, 24:508-16.","journal-title":"Health Psychol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/pon.747","article-title":"Pessimism as a predictor of emotional morbidity one year following breast cancer surgery","volume":"13","author":"Schou I","year":"2004","unstructured":"Schou I, Ekeberg \u00d8, Ruland CM, Sandvik L, K\u00e5resen R. Pessimism as a predictor of emotional morbidity one year following breast cancer surgery. Psychooncology. 2004, 13:309-20. 10.1002\/pon.747","journal-title":"Psychooncology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/412394-follicular-lymphoma-of-the-breast-with-secondary-central-nervous-system-transformation-and-concurrent-metastatic-melanoma-report-of-a-rare-case","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T06:04:28Z","timestamp":1758866668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/412394-follicular-lymphoma-of-the-breast-with-secondary-central-nervous-system-transformation-and-concurrent-metastatic-melanoma-report-of-a-rare-case"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.93232","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,25]]}}}